摘要
目的测定新辅助化疗后患者靶控输注（target-controlled infusion，TCI）依托咪酯意识消失时的半数效应室靶浓度（ECm）。方法90例ASAI或Ⅱ级，同时期行乳腺癌切除手术的乳腺癌患者，根据术前是否接受新辅助化疗以及化疗方案分为未化疗组（I组），紫杉醇化疗4周期组（Ⅱ组），药物联合化疗4周期组（Ⅲ组）。按序贯法给予依托咪酯靶控输注10min，相邻效应室靶浓度之间比率为1．25。结果未化疗组患者意识消失的半数效应室靶浓度（EC。）为0．58mg／L，95％可信区间为0．53mg，L～0．63mg／L。紫杉醇化疗组患者意识消失的Ec50为0．34mg／L，95％可信区间为0．32mg／L～0．37mg／L。药物联合化疗组患者意识消失的Ec50为0．35mg／L，95％可信区间为0．32mgCL～0．39mg／L。结论乳腺癌新辅助化疗后患者靶控输注依托咪酯时意识消失的EC50低于未化疗患者。
Objective To determine the Effcet-site EC50 of etomidate to cause loss of consciousness in patients who accepted adjuvant chemotherapy. Methods According to the therapeutic method before their operation,ninety breast cancer patients undergoing elective operations were allocated to 3 groups： non-adjuvant chemotherapy group （group I ,n=30）, Taxol group （group Ⅱ ,n=30）,Adriamycine＋Cyclophosphamide＋5-Fu group （group Ⅲ,n=30）. TCI etomidate was given by＂up and down ＂method for l0 min in each group. The ration of two close effect-site concentrations was 1.25. Record the state of consciousness of each patient. Results The EC50 in non-adjuvant chemotherapy group was 0.58 mg/L, the 95% confidence level was 0.53 mg/L-0.63 mg/L. The ECs0 in Taxol group was 0.34 mg/L,the 95% confidence level was 0.32 mg/L-0.37 mg/L. The EC50 in non-adjuvant chemotherapy group was0.35μg/ml,the 95% confidence level was0.32mg/L-0.39 mg/L. Conclusion The ECs0 of etomidte to cause loss of consciousness in adjuvant chemotherapy group is low than control group.
出处
《国际麻醉学与复苏杂志》
CAS
2011年第1期48-50,124,共4页
International Journal of Anesthesiology and Resuscitation
基金
基金项目：北京肿瘤医院院内基金资助（08-09）
